Randomized
Her recent ECG and 2D echo reports were essentially normal. She is wary regarding lowering her blood pressure since she read that BP reductions in her age group to normal levels did not translate to reduction in mortality. However, she expresses her concern regarding the risk of heart failure and stroke if she did not reduce her blood pressure.
Clinical Question: Among hypertensive patients aged 80 years or older, how effective is antihypertensive therapy in reducing the risk of stroke, heart failure, and death from cardiovascular and any cause?
Appraising Validity
Interpreting Results
Assessing Applicability:
Biological Issues: The results can be applied to our patient, since her characteristics fit with the characteristics of the patients included in the study. The study included almost 40% coming from Asia and the other majority coming from Europe. The question regarding the effectiveness of the study intervention based on racial differences can be disregarded. In totality, the results of this journal article can be applied to our patient's case.
Socioeconomic Issues: None

Individualizing Results
Patient's baseline risk for developing major cardiovascular event as well as risk factors for an adverse outcome is comparable to that of the study population. Based on the NNTs, if we treat 200 patients with Indapamide SR 1.5 mg (P25/ tab), Indapamide 1.5 mg + Perindopril 2 mg (P39/ tab), and Indapamide 1.5 mg + Perindopril 4 mg (P48/tab) daily for 1 year to achieve a target blood pressure of 150/80 mmHg, overall expense would be P1,825,000.00, P2,847,000.00, and P3,504,000, respectively, and this amount of money spent could prevent 2 strokes, 2 deaths from stroke, 5 deaths from any cause, 3 deaths from cardiovascular cause, and 4 CHF. Adverse effects such as hypokalemia, hyperglycemia, and azotemia may occur negligibly, which in the study showed no significant difference among the patients in both treatment groups in the mean baseline changes from baseline in the serum potassium, glucose and creatinine, respectively. Given the high cost of treatment but negligible adverse effects, the patient will be more likely to benefit from the treatment.
Author's Conclusion
The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial.
Bottomline...
Treatment with Indapamide (sustained release), with or without Perindopril, in persons aged 80 years or older is beneficial in terms of reducing risk of stroke, CHF, and death, with minimal adverse effects. The cost of treatment will still have to be considered. Clinical Scenario: A general practitioner friend of yours is concerned about requesting a 2DED for one of his financially challenged patients who complains of easy fatigability and has borderline cardiomegaly on chest x-ray and atrial fibrillation in ECG. He asks you if there is any blood test that could help verify the presence of structural heart disease. Being a fellow-in-training in cardiology, you ask one of your mentors who suggested the use of NT pro-BNP. Your friend requested the test and the result was elevated at 1000 pg/ml. However, on further reading, you note that NT-pro-BNP may be increased in cases of atrial fibrillation. You wonder then if this test can be applicable to your friend's patient after all.
Clinical Question: Among patients with cardiac dysrhythmia, how well can NT pro-BNP diagnose structural heart disease? Citation: Shelton RJ, Clark AL, Goode. Rigby A, and Cleland JGF. The Diagnostic utility of Nterminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation Eur Heart J. 2006;27, 2353-2361. In our clinical scenario, the level of NT pro-BNP was 1000 pg/ml. At this level, in detecting structural heart disease in patients with AF, the sensitivity of NT pro-BNP is 90 %, specificity 50%, positive predictive value 83%, negative predictive value 65%. The likelihood ratio is 1.8; thus there is a 1.8-fold increase in the odds of disease (i.e. structural heart disease) in patients with AF given an NT-pro-BNP reset of 1000 pg/ ml.
Appraising Directness
Assessing Applicability:
Biological Issues:The results can be applied to our clinical setting. The population included patients, both in sinus rhythm as well as in atrial fibrillation, aged 69 years and above, including both males and females in almost equal number. There was no mention of the race of the study participants. Co-morbid conditions included ischemic heart disease, hypertension, diabetes and cerebrovascular disease. However, the diagnostic utility of the test is affected by the age of the patient and the cardiac rhythm whether atrial fibrillation or sinus rhythm.
Socioeconomic Issues: NT-pro-BNP is an expensive diagnostic test which is available only in a few centers in Metro Manila, presently unavailable at the Philippine Heart Center.
Individualizing Results
The patient in our clinical scenario has an NT-proBNP level of 1000 pg/ml. Using the Fagan's nomogram, if I set the pretest probability at 90% and plot it with a likelihood ratio of 1.8, then the post-test probability of structural heart disease is 90%.
Author's Conclusion
Bottomline...
NT-pro-BNP at higher values, i.e > 1000 pg/ml has diagnostic utility for structural heart disease in patients with atrial fibrillation.
Reference:
Shelton RJ, Clark AL, Goode. Rigby A and Cleland JGF. The Diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation Eur Heart J. 2006; 27, 2353-2361.
Editor's Note:
CATs are critical appraisal of a journal article that addresses a clinical question. Clinical questions are often encountered during patient encounters, reading articles and conferences. Given the flux of medical information available, CATs can be considered as tools that can be use by a busy clinician or a trainee or an academician to select articles applicable to their clinical question. In doing CATs, we assess the directness, validity and applicability of an article; interpret and individualize the results; and arrive at a reviewer's conclusion or clinical bottomline.
The reviewers of CATs published here are fellowsin-training. They were given workshops in doing CATs and they have been practicing doing CATs as part of their training. The appraisal of the articles are made by them and statements and opinions expressed by them do not necessarily reflect those of the editors and publishers. Atrial fibrillation causes an elevation of NT-proBNP in patients without major structural heart disease and across the entire spectrum of such disease. If NT-pro BNP is to be used as a screening tool in patients with AF, significant adjustments to current proposed cut-off values are required to maintain its diagnostic utility.
74 Phil Heart Center J January -April 2012 NT-pro-BNP is not available in all hospitals. Its present cost is P3,650. Compared with a 2DED which was used as a reference standard in this trial, the price of the 2 tests are comparable. We should thus inform our patient and let him/her make an informed choice about which diagnostic test to be performed.
